Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

Capecitabine 15Oxaliplatin 10spartalizumab 6Irinotecan 6tislelizumab 4Immune Checkpoint Inhibitors 4toripalimab 3Neoadjuvant Therapy 3sintilimab 2camrelizumab 2Radiation 2Fluorouracil 2Celecoxib 2nimotuzumab 1XELOX 1Thymalfasin 1Radiotherapy 1Leucovorin 1Injections 1HMPL-013 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer × tislelizumab × Clear all
NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
130 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT06056804 2025-04-02

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Hebei Medical University Fourth Hospital

Phase 2 Completed
118 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT04989855 2021-08-04

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡